Pre-earnings options volume in Inhibrx (INBX) is normal with calls leading puts 4:1. Implied volatility suggests the market is anticipating a move near 7.3%, or $6.02, after results are released. Median move over the past eight quarters is 3.0%.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INBX:
- Is INBX a Buy, Before Earnings?
- Largest borrow rate increases among liquid names
- Inhibrx’s Promising Study on INBRX-106 for Advanced Head and Neck Cancer
- Inhibrx Biosciences Advances Cancer Treatment with INBRX-106 Study Update
- Inhibrx’s Phase 2 Study on INBRX-109: A Potential Breakthrough in Chondrosarcoma Treatment